IGM Biosciences Inc (FRA:1K0)
€ 13.9 -0.4 (-2.8%) Market Cap: 863.57 Mil Enterprise Value: 663.99 Mil PE Ratio: 0 PB Ratio: 7.62 GF Score: 29/100

IGM Biosciences Inc at Bank of America Biotech SMID Cap Conference Transcript

Dec 08, 2022 / 07:45PM GMT
Release Date Price: €18.7 (+4.47%)
Operator

The program is about to begin. (Operator Instructions) At this time, it is my pleasure to turn the program over to your host, Greg Harrison.

Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Hi and welcome to the Bank of America SMID Biotech Virtual Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, I'm happy to introduce IGM Biosciences represented by Fred Schwarzer, CEO. Thanks for joining us, everybody. And for those of you out there watching, if you'd like to send any questions, I'm happy to ask them on your behalf.

Questions & Answers

Gregory Allen Harrison;Fred M. Schwarzer
BofA Securities, Research Division - Analyst;IGM Biosciences, Inc. - CEO, President &

Fred, let's go ahead and just jump right into the Q&A. Maybe just with an intro for people who maybe are less up to speed on IGM, what is differentiating about the IGM class of antibodies as therapeutics relative to traditional IgG antibody treatment?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot